Brazil suspends $324-mn Covid-19 vaccine deal with Bharat Biotech

The deal to buy 20 million doses of Bharat Biotech's Covaxin shot has become a headache for Bolsonaro after whistleblowers went public with alleged irregularities

Covaxin, bharat biotech, covid, coronavirus, vaccine, drugs, medicine, pharma
Bolsonaro, whose popularity has faded as Brazil’s Covid-19 death toll climbed past 500,000, has denied any wrongdoing, saying on Monday he was not aware of any irregularities
Gabriel Stargardter | Reuters Rio de Janeiro
2 min read Last Updated : Jul 01 2021 | 2:12 AM IST
Brazil will suspend a $324-million contract for Covid-19 vaccine from India that has mired President Jair Bolsonaro in accusations of irregularities, the health minister said on Tuesday, following guidance by the federal comptroller, the CGU.

The deal to buy 20 million doses of Bharat Biotech’s Covaxin shot has become a headache for Bolsonaro after whistleblowers went public with alleged irregularities. One health ministry official said he alerted the president about his concerns.

Bolsonaro, whose popularity has faded as Brazil’s Covid-19 death toll climbed past 500,000, has denied any wrongdoing, saying on Monday he was not aware of any irregularities.

But thorny questions persist, and may pose problems for him ahead of next year’s presidential vote.


Health Minister Marcelo Queiroga told a news conference his team would investigate the accusations during the suspension.

“According to the preliminary analysis of the CGU, there are no irregularities in the contract but, for compliance, the health ministry chose to suspend the contract,” the ministry said in a statement.

CNN Brasil had earlier reported that the ministry had decided to cancel the contract.

Brazilian federal prosecutors have opened an investigation, citing comparatively high prices of about $15 a dose, quick talks and pending regulatory approvals as red flags.

The deal is also being probed by a Senate panel investigating Brazil’s handling of the pandemic.

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Topics :CoronavirusBrazilBharat BiotechCoronavirus VaccineVaccinationVaccinecorruptionJair Bolsonaro

Next Story